Literature DB >> 16370086

Tipranavir.

Charles Flexner1, Guy Bate, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16370086     DOI: 10.1038/nrd1907

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  11 in total

1.  Analysis of non-peptidic compounds as potential malarial inhibitors against Plasmodial cysteine proteases via integrated virtual screening workflow.

Authors:  Thommas M Musyoka; Aquillah M Kanzi; Kevin A Lobb; Özlem Tastan Bishop
Journal:  J Biomol Struct Dyn       Date:  2016-01-28

Review 2.  Emerging principles in protease-based drug discovery.

Authors:  Marcin Drag; Guy S Salvesen
Journal:  Nat Rev Drug Discov       Date:  2010-09       Impact factor: 84.694

3.  High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.

Authors:  Anuradha Balasubramanian; Mark Manzano; Tadahisa Teramoto; Rajendra Pilankatta; Radhakrishnan Padmanabhan
Journal:  Antiviral Res       Date:  2016-08-15       Impact factor: 5.970

4.  Role of tipranavir in treatment of patients with multidrug-resistant HIV.

Authors:  Joshua D Courter; Colleen J Teevan; Michael H Li; Jennifer E Girotto; Juan C Salazar
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

Review 5.  HIV protease inhibitors in gut barrier dysfunction and liver injury.

Authors:  Xudong Wu; Yunzhou Li; Kesong Peng; Huiping Zhou
Journal:  Curr Opin Pharmacol       Date:  2014-08-06       Impact factor: 5.547

6.  Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.

Authors:  S Muzammil; A A Armstrong; L W Kang; A Jakalian; P R Bonneau; V Schmelmer; L M Amzel; E Freire
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

Review 7.  Serine Proteases of Malaria Parasite Plasmodium falciparum: Potential as Antimalarial Drug Targets.

Authors:  Asrar Alam
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-03-11

8.  The Activity of a Hexameric M17 Metallo-Aminopeptidase Is Associated With Survival of Mycobacterium tuberculosis.

Authors:  Andre F Correa; Izabela M D Bastos; David Neves; Andre Kipnis; Ana P Junqueira-Kipnis; Jaime M de Santana
Journal:  Front Microbiol       Date:  2017-03-27       Impact factor: 5.640

9.  Synthesis and in vitro evaluation of substituted 3-cinnamoyl-4-hydroxy-pyran-2-one (CHP) in pursuit of new potential antituberculosis agents.

Authors:  Zubair Shanib Bhat; Hafiz Ul Lah; Muzafar Ahmad Rather; Mubashir Maqbool; Tabassum Ara; Zahoor Ahmad; Syed Khalid Yousuf
Journal:  Medchemcomm       Date:  2017-12-06       Impact factor: 3.597

Review 10.  Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.

Authors:  Usman Arshad; Henry Pertinez; Helen Box; Lee Tatham; Rajith K R Rajoli; Paul Curley; Megan Neary; Joanne Sharp; Neill J Liptrott; Anthony Valentijn; Christopher David; Steve P Rannard; Paul M O'Neill; Ghaith Aljayyoussi; Shaun H Pennington; Stephen A Ward; Andrew Hill; David J Back; Saye H Khoo; Patrick G Bray; Giancarlo A Biagini; Andrew Owen
Journal:  Clin Pharmacol Ther       Date:  2020-06-14       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.